Weight Loss Pills: Effectiveness and Risks

Obesity is a chronic, relapsing disease in which pharmacotherapy complements nutrition, physical activity, and behavioral support. Pills and injectable medications reduce excessive appetite, slow gastric emptying, improve satiety, or reduce fat absorption, helping to achieve clinically significant weight loss and maintain the results. [1]

Professional societies recommend considering medications only if lifestyle changes have not yielded sustainable results or if obesity complications already exist. "Sustained results" are typically defined as weight loss of 5% or more with a maintained effect. Efficacy thresholds and treatment continuation guidelines are outlined in clinical guidelines. [2]

Importantly, a number of treatments have demonstrated not only weight loss but also improvements in "hard" outcomes. In the SELECT study in obese people without diabetes, a semaglutide-based drug reduced the risk of major cardiovascular events by approximately 20% compared to placebo. This shifts the focus from "aesthetics" to reducing real life risks. [3]

Anti-obesity medications are always prescribed as part of a comprehensive program: energy-deficient diets, increased activity, addressing overeating triggers, sleep, and stress management. Pharmacotherapy enhances these measures, helps overcome physiological "weight-protection" mechanisms, and thereby increases the likelihood of long-term success. [4]

The modern approach is personalization. Drug selection depends on the underlying disease, target priorities, tolerability, route of administration, cost, and availability in a particular country. Different classes have different effects on appetite, gastrointestinal symptoms, blood pressure, heart rate, and risk of gallstones. [5]

Table 1. When is pharmacotherapy indicated for obesity?

Clinical situation	Who is it indicated for?	The goal of therapy	Notes
No complications of obesity	Body mass index ≥30	Weight loss ≥5% in 3-6 months	Evaluation of response and tolerability every 12-16 weeks
There are complications	Body mass index ≥27 in the presence of comorbidity	The priority is to reduce risks and symptoms	Associated goals: sleep, glycemia, blood pressure
Failure is only in the way of life	Any of the above	Strengthening the effect of changes	Combined with behavioral support
Relapse of weight gain	Individuals with a history of weight loss	Repeatedly achieving and maintaining a goal	A change in drug class is possible
Preparing for or after bariatric surgery	According to the readings	Risk optimization and result retention	Individual selection of the scheme

The source of the criteria is the guidelines for the management of obesity in adults. [6]

Main classes of drugs

Intestinal lipase inhibitors. Orlistat reduces the breakdown and absorption of dietary fat in the intestine, leading to moderate weight loss during dieting. This effect is accompanied by fatty stools and flatulence when the diet is excessively fat-containing, so nutrition education and multivitamin use are required at intervals between orlistat use. [7]

A combination of naltrexone and bupropion. It acts on the hunger and reward centers, reducing food cravings and episodes of overeating. May increase blood pressure and heart rate; contraindicated in uncontrolled hypertension and seizure disorders; titrating the dose weekly reduces the risk of side effects. [8]

Glucagon-like peptide-1 receptor agonists. Liraglutide and semaglutide enhance satiety, reduce spontaneous calorie intake, and have been shown to produce double-digit weight loss when combined with lifestyle interventions. The regimen includes a gradual dose increase to improve tolerability of gastrointestinal effects. [9]

A dual agonist of the glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptors, tirzepatide demonstrated even more pronounced weight loss in the SURMOUNT programs, as well as a high proportion of patients achieving a loss of 15% or more. Marketing authorizations and country-specific clarifications are in effect in the European Union. [10]

Melanocortin receptor 4 agonists for rare genetic forms. Setmelanotide is a targeted therapy for specific inherited defects of the leptin-melanocortin pathway and is not used for common forms of obesity. Prescription requires confirmed genetic testing. [11]

Table 2. Classes, mechanism, examples and method of application

Class	Mechanism of key action	Examples	Form
Lipase inhibitor	Dietary fat absorption block	Orlistat	Capsules
Central action	Modulation of appetite centers	Naltrexone plus bupropion	Extended-release tablets
Glucagon-like peptide-1 receptor agonist	Increased satiety, slower gastric emptying	Liraglutide, semaglutide	Injections, for semaglutide also capsules for other indications
Dual agonist of glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptors	The combined effect of satiety and food intake control	Tirzepatide	Injections
Melanocortin receptor 4 agonist	Correction of congenital deficiencies in hunger regulation	Setmelanotide	Injections

Details of registration and instructions - materials of drug agencies. [12]

How effective are they: expected effectiveness and impact on risks

In meta-analyses and guidelines, drugs are ranked by their potency in weight loss. Modern incretin agents demonstrate the most pronounced effect. Semaglutide in the STEP program for obese adults resulted in an average weight loss of approximately 15%, in addition to lifestyle changes. [13]

In obese individuals without diabetes, tirzepatide demonstrated a weight loss of approximately 20% by week 72, with the vast majority of participants losing 5% or more, and a high proportion losing 15% or more. Long-term follow-up data indicate that this effect is maintained with maintenance therapy. [14]

Liraglutide provides a moderate but sustained effect, particularly in patients with increased appetite and cravings for overeating, if the daily injection regimen and behavioral support are followed. Real-world data support its applicability in routine practice. [15]

Orlistat provides a small but statistically significant additional weight loss when compared to diet and is useful for patients willing to strictly control dietary fat and take multivitamins. It may be an option for those with intolerance to centrally acting agents. [16]

Of particular importance is the effect on cardiovascular outcomes. In obese, high-risk individuals without diabetes, semaglutide reduced the risk of major cardiovascular events by one-fifth, confirming the benefits of the therapy beyond the scale. Regulatory expansion of the indications is underway. [17]

Table 3. Comparison of effectiveness across key studies

Preparation	Population	Duration	Average weight loss	Other effects
Semaglutide	Adults with obesity	68 weeks	About 15%	Improving risk factors
Tirzepatide	Adults with obesity	72 weeks	About 20%	High loss rate ≥15%
Liraglutide	Adults with obesity	56 weeks	About 6-8%	Reduced food cravings
Orlistat	Adults with obesity	52 weeks	3-5%	Decreased fat absorption

Numbers are averaged across major STEP and SURMOUNT programs and reviews. [18]

Safety, contraindications and monitoring

Glucagon-like peptide-1 receptor agonists and dual agonists are characterized by dose-dependent gastrointestinal effects: nausea, a feeling of fullness, and, less commonly, vomiting and constipation. These effects usually decrease with slow titration and adherence to a dietary regimen with smaller portions and adequate protein. [19]

The risk of cholelithiasis and cholecystitis is slightly increased, especially with high doses, long-term use, and rapid weight loss. Patients with risk factors for cholelithiasis require prevention, symptom control, and timely diagnosis. [20]

Data on the risk of pancreatitis are conflicting. Recent reviews of semaglutide have shown no increased risk compared to placebo, but in real-world practice, any acute abdominal symptoms require the exclusion of pancreatitis and biliary tract disease. The decision to continue therapy is made on an individual basis. [21]

The combination of naltrexone and bupropion is contraindicated in uncontrolled hypertension and seizure disorders and requires blood pressure and pulse rate monitoring, as well as a stepwise benefit-risk assessment at week 16. Each country has its own regulatory guidelines. [22]

Orlistat can reduce the absorption of fat-soluble vitamins, so daily multivitamins are recommended, spaced apart, and a diet should be planned with limited fat. When used correctly, vitamin levels usually remain within normal limits. [23]

Table 4. Contraindications and key precautions

Preparation	Main contraindications	What to control
Liraglutide, semaglutide, tirzepatide	Individual contraindications from the instructions; alertness to gallstone disease; symptoms of pancreatitis	Gastrointestinal symptoms, dehydration, signs of biliary colic
Naltrexone plus bupropion	Uncontrolled hypertension, seizure disorders, pregnancy	Blood pressure, pulse, sleep, mood
Orlistat	Malabsorption syndrome, cholestasis, pregnancy	Stool, flatulence, vitamins A, D, E, K with long-term use

Summary formulations - according to official documents for drugs. [24]

How to choose a drug for a patient

If prediabetes or type 2 diabetes are the primary consideration, incretin agents are preferred due to their significant weight loss and beneficial effects on cardiometabolic factors. If cardiovascular risk is present, the proven reduction in events with semaglutide will be an additional argument. [25]

For cravings and difficulties controlling impulsive eating, naltrexone and bupropion are considered, with mandatory blood pressure and sleep monitoring. This option is appropriate when the injectable format is unsuitable or the incretin class is contraindicated. [26]

Orlistat may be an option for those with a limited budget or unwilling to use systemic anorexigenic mechanisms, provided the patient is prepared to adhere to strict dietary guidelines and regular multivitamin intake. It is important to address common dietary errors in advance to reduce gastrointestinal side effects. [27]

The route of administration and the willingness to titrate the dose regularly influence adherence. Once-weekly injection regimens are generally easier to manage than daily injections, and gradual dose increases reduce the rate of discontinuation due to nausea. Shared decision-making increases the chances of treatment retention. [28]

Availability and approval status vary by region. In the European Union, semaglutide, liraglutide, naltrexone with bupropion, and orlistat are available; tirzepatide is subject to indication and update decisions reflected in the Medicines Agency's filings. A broader spectrum of medications is approved in the United States, including a combination of phentermine and topiramate. [29]

Table 5. Quick selection by clinical priorities

Priority	Preferred classes	What to avoid
Cardiometabolic risk	Semaglutide, tirzepatide	Central stimulants without evidence of outcomes
Compulsive overeating	Naltrexone plus bupropion	Drugs with severe nausea and a low tolerance threshold
Limited budget	Orlistat	Complex injection regimens with low adherence
The need for maximum weight loss	Tirzepatide, semaglutide	Poorly effective options
Planning a pregnancy	Discontinuation of any anti-obesity therapy	Any medications during pregnancy and lactation

Recommendations are based on guidelines and instructions for the drugs. [30]

Prescribing tactics, titration and monitoring of effectiveness

The initial goal is to achieve a weight loss of at least 5% over 3-6 months and maintain the result. If there is no reduction by 12-16 weeks on the maintenance dose, a change in class or a revision of the behavioral and nutritional program is considered. This algorithm allows for the rational use of resources and avoids unnecessary exposure. [31]

Incretin agents are titrated stepwise at weekly or longer intervals. This reduces the incidence of nausea and allows for the selection of the minimum dose appropriate for the individual patient. Detailed titration scales are provided in the official product information. [32]

Monitoring includes weight, waist circumference, blood pressure, well-being, tolerance, and target biomarkers as indicated. For orlistat, vitamin monitoring is added during long-term use; for naltrexone with bupropion, regular blood pressure and pulse rate measurements are included. If gallstones or pancreatitis are suspected, prompt examination is required. [33]

Therapy is not stopped abruptly without reason. Once the goal is reached, a maintenance strategy is discussed: continuing the maintenance dose, strengthening behavioral skills and a diet with sufficient protein, and developing a "vacation and holiday plan" to avoid losing control during trigger periods. [34]

In cases of severe morbidity or insufficient response to drug therapy, metabolic surgery is considered. Pre- and post-operative medications help optimize risks and maintain results, but the decision is made by a multidisciplinary team. [35]

Table 6. Practical scheme of management

Stage	What are we doing?	Checkpoints
Start	We define goals and choose a class	Nutrition and trigger education
Titration	Slowly increase the dose	Gastrointestinal symptoms, blood pressure, pulse
Evaluation of the answer	Weeks 12-16 on maintenance dose	Weight loss ≥5% and tolerance
Long-term management	Maintenance dose, behavioral support	Weight maintenance, relapse prevention
Escalation	If the answer is insufficient, the class will be changed.	Reassessment of risks and objectives

The algorithm complies with modern recommendations. [36]

Frequently asked questions

Can different antiobesity drugs be combined? Routine combinations are generally not recommended due to insufficient evidence on safety and outcomes; sequential class switching is preferred in the absence of response. Exceptions are strictly indicated and under close observation. [37]

How many months is treatment prescribed? This is a chronic condition, so the duration is measured in months and years, with periodic assessments of benefits and risks. Discontinuation is often accompanied by some weight gain, so a maintenance strategy is discussed in advance. [38]

What should you do if you experience nausea while taking incretins? Slow down titration, reduce portion sizes, distribute protein evenly, and drink enough water. If symptoms persist, consider reducing the dose or switching classes. [39]

Do I need to have vitamin tests while taking orlistat? During long-term use, it's appropriate to monitor fat-soluble vitamin levels and prescribe multivitamins promptly. [40]

Who is contraindicated for obesity pills? Pregnancy and lactation are absolute contraindications for all classes. There are also specific contraindications: seizure disorders for naltrexone and bupropion, malabsorption syndrome for orlistat, and so on. The decision is made by a doctor based on the instructions for the specific medication. [41]

Table 7. What is considered treatment success and when to change tactics

Period	Criteria of success	Actions in case of insufficient response
Weeks 12-16	Weight loss ≥5%	Check titration, administration technique, nutrition; consider changing class
Months 6-12	Stabilization with further reduction to 10-15% according to indications	Strengthen behavioral support, assess factors that interfere with adherence
Year and beyond	Maintaining results and controlling complications	Individual retention strategy, relapse prevention

The thresholds are consistent with the guidelines' approaches.[42]

A quick guide to frequently asked questions about medications

• Semaglutide. Pronounced weight loss, proven reduction in major cardiovascular events in obese, high-risk individuals. Typical effects include nausea and early satiety; slow titration is important. [43]
• Tirzepatide. One of the most potent weight-loss agents, with a high success rate of 15% or more. Requires careful titration and gallbladder monitoring. [44]
• Liraglutide: Daily regimen, moderately effective, useful for cravings when satiety is important. [45]
• Naltrexone plus bupropion. Appropriate for severe food cravings; blood pressure and pulse monitoring required. Evaluation of appropriateness at week 16. [46]
• Orlistat. A budget option for those prepared to follow strict dietary guidelines and take multivitamins. [47]

Important: the specific choice, dose, duration and monitoring are determined by the attending physician during an in-person consultation, taking into account the clinical picture and the official instructions for the drug. [48]